Intravenous thrombolysis for acute stroke

Neurology

Volumn 49, Issue 1, 1997, Pages 14-20

  Lyden, P D ^a,b,h   Grotta, J C ^c   Levine, S R ^d   Marler, J R ^e   Frankel, M R ^f   Brott, T G ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e National Institute of Neurological Disorders   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^h NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN SCINTISCANNING; DRUG MONITORING; FIBRINOLYTIC THERAPY; HUMAN; MEDICAL LITERATURE; MEDICAL RECORD; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0030789126     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.1.14     Document Type: Review

References (47)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
2. Del Zoppo GJ. Thrombolytic therapy in cerebrovascular disease. Curr Concept Cerebrovasc Dis 1988;23:7-12.
3. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976-982.
4. Zivin JA, Lyden PD, DeGirolami U, et al. Tissue plasminogen activator: reduction of neurologic damage after experimental embolic stroke. Arch Neurol 1988;45:387-391.
5. Penar PL, Greer CA. The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia. Yale J Biol Med 1987;60:233-234.
6. Overgaard K, Sereghy T, Boysen G, Pedersen H, Diemer NH. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model. Stroke 1992;23:1167-1174.
7. Kissel P, Chehrazi B, Seibert JA, Wagner FC. Digital angiographic quantification of blood flow dynamics in embolic stroke treated with tissue-type plasminogen activator. J Neurosurg 1987;67:399-405.
8. Lyden PD, Zivin JA, Clark WA, et al. Tissue plasminogen activator mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology 1989; 39:703-708.
9. Phillips DA, Fisher M, Smith TW, Davis MA. Thrombolysis with t-PA after experimental stroke. Ann Neurol 1988;23:391-394.
10. Chehrazi BB, Seibert JA, Kissel P, Hein L, Brock JM. Evaluation of recombinant tissue plasminogen activator in embolic stroke. Neurosurgery 1989;24:355-360.
11. Phillips DA, Davis MA, Fisher M. Selective embolization and clot dissolution with t-PA in the internal carotid artery circulation of the rabbit. Am J Neuroradiol 1988;9:899-902.
12. Carter LP, Guthkelch AN, Orozco J, Temeltas O. Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model. Stroke 1992;23:883-888.
13. Zivin JA, Fisher M, DeGirolami U, Hemenway CC, Stashak KA. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985;230:1289-1292.
14. Del Zoppo GJ, Copeland BR, Anderchek K, Hacke W, Koziol JA. Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction. Stroke 1990;21: 596-601.
15. Lyden PD, Madden KP, Clark WM, Sasse KC, Zivin JA. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits. Stroke 1990;21:1589-1593.
16. Clark WM, Madden KP, Lyden PD, Zivin JA. Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits. Stroke 1991;22:872-876.
17. Saku Y, Choki J, Waki R, et al. Hemorrhagic infarct induced by arterial hypertension in cat brain following middle cerebral artery occlusion. Stroke 1990;21:589-595.
18. Fisher CM, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. J Neuropathol Exp Neurol 1951;10:92-93.
19. Horowitz SH, Zito JL, Donnarumma R, Patel M, Alvir J. Computed tomographic-angiographic findings within the first five hours of cerebral infarction. Stroke 1991;22:1245-1253.
20. Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev 1993;5:1-16.
21. Hornig CR, Bauer T, Simon C, Trittmacher S, Dorndorf W. Hemorrhagic transformation in cardioembolic cerebral infarction. Stroke 1993;24:465-468.
22. Toni D, Fiorelli M, Bastianello S, et al. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology 1996;46:341-345.
23. Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988;19:802-812.
24. Faris AA, Hardin CA, Poser CM. Pathogenesis of hemorrhagic infarction of the brain. Arch Neurol 1963;9:468-472.
25. Hain RF, Westhaysen PV, Swank RL. Hemorrhagic cerebral infarction by arterial occlusion: an experimental study. J Neuropathol Exp Neurol 1952;11:34-43.
26. Ogata J, Yutani C, Imakita M, et al. Hemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke. Stroke 1989;20:876-883.
27. Dandapani BK, Suzuki S, Kelley RE, Reyes-Inglesias Y, Duncan RC. Relation between blood pressure and outcome in intracerebral hemorrhage. Stroke 1995;26:21-24.
28. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976;7:135-142.
29. Hanaway J, Torack R, Fletcher AP, Landau WM. Intracranial bleeding associated with urokinase therapy for acute ischemic hemispheral stroke. Stroke 1976;7:143-146.
30. Meyer JS, Gilroy J, Barnhart ME, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism: randomized evaluation of intravenous streptokinase. In: Millikan CH, Siekert RG, Whisnant JP, eds. Cerebral Vascular Diseases, Fourth Princeton Conference. New York: Grune and Stratton, 1965: 200-213.
31. Del Zoppo GJ, Copeland BR, Waltz TA, Zyroff J, Plow EF, Harker LA. The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke 1986;17:638-643.
32. Del Zoppo GJ, Ferber A, Otis S, et al. Local intra-arterial fibrinolytic therapy in acute carotid territory stroke. Stroke 1988;19:307-313.
33. Hacke W, Zeumer H, Ferbert A, Bruckmann H, Del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988;19:1216-1222.
34. Zeumer H, Freitag H-J, Zanella F, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (rt-PA). Neuroradiology 1993;35:159-162.
35. Ringelstein EB, Biniek R, Weiller C, Ammeling B, Nolte PN. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 1992;42:289-298.
36. von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992;23:646-652.
37. Brott TG, Haley EC Jr, Levy DE, et al. Urgent therapy for stroke: Part 1. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-640.
38. Haley EC Jr, Levy DE, Brott TG, et al. Urgent therapy for stroke: Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23: 641-645.
39. Del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78-86.
40. Haley EC, Brott TG, Sheppard GL, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993;24:1000-1004.
41. Bratina P, Greenberg L, Pasteur W, Grotta JC. Current emergency department management of stroke in Houston, Texas. Stroke 1995;26:409-414.
42. Lyden PD, Rapp K, Babcock T, Rothrock J. Ultra-rapid identification, triage, and enrollment of stroke patients into clinical trials. J Stroke Cerebrovasc Dis 1994;4:106-113.
43. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-1514.
44. Hommel M, Boissel JP, Cornu C, et al. Termination of streptokinase in severe acute ischaemic stroke. Lancet 1995;345: 57.
45. Donnan GA, Hommel M, Davis SM, McNeil JJ. Streptokinase in acute ischaemic stroke. Lancet 1995;346:56.
46. Donnan GA, Davis SM, Chambers BR, et al. Trials of streptokinase in severe acute ischaemic stroke. Lancet 1995;345: 578-579.
47. National Stroke Association Consensus Statement. Stroke: the first six hours. Emergency evaluation and treatment. Stroke Clinical Updates, National Stroke Association, 1997.